Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia
23/4 07:18
(RTTNews) - Sanofi - Aventis Groupe said results from the LUNA 3 phase 3 study showed that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia. The safety profile w...